Kevin Bennett's questions to Biostem Technologies Inc (BSEM) leadership • Q2 2024
Question
Kevin Bennett posed two questions regarding the status of BioStem's patent portfolio and whether the high distribution costs associated with AmnioWrap2 could be lowered.
Answer
Executive Jason Matuszewski addressed the IP question, stating the portfolio is expanding and includes over 65 patents in various phases, covering product use and technology from the Auxocell acquisition. Michael Fortunato explained the distribution costs, clarifying that the bona fide service arrangement with Venture Medical is a fair market value fee for an outsourced sales force, logistics, and education, which the company views as a strategic alternative to building an in-house team.